Aesthetics, Orthobiologics, and Therapeutics Wonder EXOMINE offers innovative solutions in Autologous Platelet Derived Exosomes Rich Plasma technology!<\/p>\n\n\n\n
EXOMINE, developed by the innovative T-LAB R&D team in the field of regenerative medicine as a result of meticulous work, is ready to meet with the experts in the field within the first quarter of 2024. <\/p>\n\n\n\n
Exomine Kit stresses the platelets and trace amounts of other blood cells in the PRP, causing the secretion of billions of vesicles. At the same time, it activates platelets with its special protocol and devices, provides an autologous plasma rich in platelet-derived exosomes.<\/p>\n\n\n\n
EXOMINE, a revolutionary product in aesthetics, orthobiologics, and therapeutics applications, aims to provide effective results in many areas such as skin regeneration, hair loss, spot treatments, joint and connective tissue treatments, and unclosed wounds.<\/p>\n\n\n\n
In the field of aesthetics, EXOMINE stimulates the production of collagen and elastin required in the field of Skin Regeneration and thus contributes to the rejuvenation of the skin by reducing fine lines and wrinkles, also developed for spot treatments; It supports rapid repair and regeneration in cases such as acne scars, sun spots and eczema, and also stops hair loss by nourishing the hairy tissue and improves hair quality by stimulating hair follicle stem cells.<\/p>\n\n\n\n
In the field of Orthobiologics, Exomine is a powerful factor in the elimination of joint and connective tissue damages, plays a vital role in increasing synovial fluid, strengthening joint and connective tissue and repairing damages with its intercellular signalling and stimulating cells.<\/p>\n\n\n\n
In the field of Therapeutics, Exomine Kit is used in most therapeutics and medicinal fields other than aesthetics and orthobiologics, is produced for patients to recover faster and continue their daily lives with its high exosome number and vitality. It is used in many therapeutic areas such as IVF, non-healing wounds, and jaw joint discomfort.<\/p>\n\n\n\n
In alignment with the research conducted by T-LAB's proficient R&D team and experienced physicians in the field, EXOMINE, the Autologous Platelet Source Exosomes Rich Plasma kit, was launched. Over the course of approximately four years of research studies, Exomine has consistently demonstrated its reliability and effectiveness by obtaining necessary laboratory results, substantiating this claim repeatedly.<\/p>\n\n\n\n
T-LAB has developed and continues its ongoing research and development efforts to combine the reliability and professionalism of autologous systems. In line with this, T-LAB has undertaken efforts to make the EXOMINE product an autologous system. Consulting with expert physicians in the field, T-LAB has determined that an autologous system will be more reliable and effective. Consequently, T-LAB has introduced the EXOMINE product to its valued patients.<\/p>\n\n\n\n
T-LAB has achieved billions of vesicles count through its completed and ongoing device and protocol studies, establishing the EXOMINE product at the forefront in the field by obtaining approximately 20 billion vesicles per mL.<\/p>\n\n\n\n
The final product, the EXOMINE Kit, with an approximate volume of 5cc, offers patients 100 billion vesicles, representing the highest vesicle count among competing products in the field.<\/p>\n\n\n\n
A high vesicle count does not mean everything, in order to classify the obtained vesicles as exosomes, it is necessary for their sizes to fall within the range of 80-120nm, undergo analysis with relevant CD markers, and exhibit high viability.<\/p>\n\n\n\n
EXOMINE Kit stresses the platelets and other blood cells in the PRP, causing the secretion of billions of vesicles. By activating platelets with special protocols and devices, it provides an autologous plasma rich in platelet-derived exosomes. These exosomes contain components that play important roles in biological processes such as mRNA, miRNA, and protein.<\/p>\n\n\n\n
Innovative PRX Tube Design and the state-of-the-art Microlyzer Blade Technology converge in the same product. <\/p>\n\n\n\n
T-LAB has developed EXOMINE technology, presenting a unique and effective approach. This innovation is merged with Microlyzer Blade Technology and Advanced PRX Tube.<\/p>\n\n\n\n
Microlyzer 600\u03bcm triggers the secretion of billions of vesicles by acting on blood cells with its specially designed blades and unique structure. This unique technology puts the blood cells under a special stress so that the exosomes necessary for tissue regeneration are produced by the cells.<\/p>\n\n\n\n
T-LAB's expert R&D team has undertaken intensive efforts to enhance vesicle release from blood cells of specific dimensions and weights, as well as to mechanically activate platelet cells. As a result of these efforts, the patented Advanced PRX Tube with a unique design has emerged. With its specialized internal design, the tube facilitates the release of billions of vesicles from cells, activation of platelet cells, and cause other blood cells to sink to the bottom. This enhances the effectiveness of the regenerative process, allowing for more successful outcomes.<\/p>\n\n\n\n
The EXOMINE Technology, combined with Microlyzer Blade Technology and the Advanced PRX Tube, is set to herald a breakthrough in autologous plasma applications enriched with platelet-derived exosomes. T-LAB's leadership in the healthcare industry, coupled with the innovative solutions and continuously evolving technology inherent in the EXOMINE product, will open doors to more effective and efficient regenerative treatments as of the year 2024. <\/p>\n\n\n\n
Since 2012, T-LAB has played a pioneering role in the field of regenerative medicine and has performed over 2 million PRP applications worldwide. T-LAB, T\u00fcrkiye's leading PRP kit manufacturer, launched EXOMINE technology, which it developed with great enthusiasm and dedication, in the last quarter of 2023.Designed through meticulous research and development efforts in response to increasing demand, EXOMINE represents a groundbreaking milestone in the field of regenerative medicine. The product has undergone rigorous testing processes, ensuring its potential as a pivotal advancement in the realm of regenerative medicine.<\/p>\n\n\n\n
The intensive R&D efforts conducted throughout the year, combined with the collaboration of experts in the field, have unveiled the impressive features of EXOMINE. Blending Microlyzer Blade Technology and Advanced PRX Tube has resulted in an innovative technology that embodies the undeniable quality of T-LAB. <\/p>\n\n\n\n
The completed testing phases have demonstrated that EXOMINE meets top-tier quality and performance standards. T-LAB has decided to announce this success on a global scale, with plans to introduce EXOMINE for use in the first quarter of 2024. <\/p>\n\n\n\n
EXOMINE's seamless harmony with the Advanced PRP Kit, Non-Enzymatic SVF Kit, and other T-LAB products will provide healthcare professionals with a broad spectrum of usage advantages. <\/p>\n\n\n\n
By launching EXOMINE, T-LAB continues to pioneer a new era in PRP applications, offering solutions in the fields of aesthetics, orthobiologics, and therapeutics with its newly introduced product at the end of 2023. As the leading brand in the regenerative medicine in T\u00fcrkiye, T-LAB once again merges innovation and quality with EXOMINE. With its innovative technologies and high-quality products, T-LAB will maintain its leadership in solutions for healthcare professionals and patients in 2024. <\/p>\n\n\n\n
<\/p>","protected":false},"excerpt":{"rendered":"
Otolog Trombosit Kaynakl\u0131 Eksozomlardan Zengin Plazma teknolojisinde Estetik, Ortobiyolojik ve Terap\u00f6tik Harikas\u0131 EXOMINE yenilik\u00e7i \u00e7\u00f6z\u00fcmler Sunuyor! Rejeneratif t\u0131p alan\u0131n\u0131n yenilik\u00e7i T-LAB Ar-Ge ekibinin titiz \u00e7al\u0131\u015fmalar sonucunda imza att\u0131\u011f\u0131 EXOMINE 2024 y\u0131l\u0131n\u0131n ilk \u00e7eyre\u011fi kapsam\u0131nda alan\u0131n\u0131n uzmanlar\u0131 ile bulu\u015fmaya haz\u0131r. EXOMINE NED\u0130R? Exomine Kit, PRP\u2019nin i\u00e7erisinde bulunan trombosit ve eser miktardaki di\u011fer kan h\u00fccrelerini strese sokarak milyarlarca vezik\u00fcl salg\u0131lanmas\u0131n\u0131 sa\u011flar. Ayn\u0131 zamanda \u00f6zel protokol\u00fc ve cihazlar\u0131 ile trombositleri aktive ederek, trombosit kaynakl\u0131 eksozomlardan zengin otolog bir plazma sunar. Estetik, Ortobiyolojik ve terap\u00f6tik uygulamalarda devrim niteli\u011finde bir \u00fcr\u00fcn olan EXOMINE, cilt rejenerasyonunda, sa\u00e7 d\u00f6k\u00fclmelerinde, leke tedavilerinde, ekle ve ba\u011f doku tedavilerinde, kapanmayan yaralar gibi bir \u00e7ok alanda etkili sonu\u00e7lar sa\u011flamay\u0131 hedefliyor. Estetik alanda; Cilt Rejenerasyonu alan\u0131nda gerekli kolajen ve elastin \u00fcretimini uyaran ve bu sayede ince \u00e7izgileri ve k\u0131r\u0131\u015f\u0131kl\u0131klar\u0131 azaltarak cildin gen\u00e7le\u015fmesine katk\u0131da bulunur, leke tedavilerine y\u00f6nelik de geli\u015ftirilen EXOMINE; akne izleri, g\u00fcne\u015f lekeleri ve egzama gibi durumlarda h\u0131zl\u0131 onar\u0131m ve rejenerasyonu destekler ayr\u0131ca sa\u00e7l\u0131 dokuyu besleyerek sa\u00e7 d\u00f6k\u00fclmelerini durdurur ve sa\u00e7 folik\u00fcl k\u00f6k h\u00fccrelerini uyararak sa\u00e7 kalitesini de art\u0131r\u0131r. Ortobiyolojik alanda; Eklem ve ba\u011f doku hasarlar\u0131n\u0131n giderilmesinde g\u00fc\u00e7l\u00fc bir fakt\u00f6r olan Exomine, h\u00fccreler aras\u0131 sinyalizasyon ve h\u00fccreleri uyarma g\u00f6revi sayesinde sinoviyal s\u0131v\u0131n\u0131n artt\u0131r\u0131lmas\u0131nda, eklem ve ba\u011f dokusunu g\u00fc\u00e7lendirerek hasarlar\u0131n onar\u0131lmas\u0131nda \u00f6nemli rol oynamaktad\u0131r. Terap\u00f6tik alanda; Estetik ve Ortobiyolojij alanlar\u0131n d\u0131\u015f\u0131nda tedavi edici ve iyile\u015ftirme alanlar\u0131n\u0131n \u00e7o\u011funda kullan\u0131lan Exomine Kit, y\u00fcksek eksozom say\u0131s\u0131 ve canl\u0131l\u0131\u011f\u0131 ile hastalar\u0131n daha h\u0131zl\u0131 iyile\u015fmesi ve g\u00fcnl\u00fck ya\u015famlar\u0131na devam edebilmesi i\u00e7in \u00fcretilmi\u015ftir. Kapanmayan yaralar, \u00e7ene eklem rahats\u0131zl\u0131\u011f\u0131 gibi bir\u00e7ok terap\u00f6tik alanda kullan\u0131lmaktad\u0131r. EXOMINE: Otolog Sistem, Milyarlarca Vezik\u00fcl, Optimum Boyut, Y\u00fcksek Canl\u0131l\u0131k T-LAB, uzman ar-ge ekibi ve alan\u0131nda uzman hekimleri ile y\u00fcr\u00fctm\u00fc\u015f oldu\u011fu \u00e7al\u0131\u015fmalar do\u011frultusunda Otolog Trombosit Kaynakl\u0131 Eksozomlardan Zengin Plazma kiti olan EXOMINE\u2019\u0131 \u00e7\u0131kard\u0131. Yakla\u015f\u0131k olarak 4 y\u0131l s\u00fcren \u00e7al\u0131\u015fmalar do\u011frultusunda \u00fcr\u00fcn\u00fcn g\u00fcvenilir ve etkili sonu\u00e7 vermesi i\u00e7in gerekli olarak laboratuvar sonu\u00e7lar\u0131n\u0131 elde ederek bunu defalarca kan\u0131tlad\u0131. Otolog Sistem EXOMINE! T-LAB geli\u015ftirmi\u015f oldu\u011fu ve devam eden ar-ge \u00e7al\u0131\u015fmalar\u0131 do\u011frultusunda otolog sistemlerin g\u00fcvenirli\u011fini ve bu konudaki profesyonelli\u011fini birle\u015ftirerek, EXOMINE \u00fcr\u00fcn\u00fcn otolog bir sitem olmas\u0131 \u00fczerine \u00e7al\u0131\u015fmalar\u0131n\u0131 ger\u00e7ekle\u015ftirdi, bu konuda alan\u0131nda uzman hekimlerinde g\u00f6r\u00fc\u015f\u00fcn\u00fc alarak otolog sistemin daha g\u00fcvenilir ve etkili olaca\u011f\u0131na karar veren T-LAB, EXOMINE \u00fcr\u00fcn\u00fcn\u00fc de\u011ferli kullan\u0131c\u0131lar\u0131na sundu. Milyarlarca Vezik\u00fcl, Optimum Boyut, Y\u00fcksek Canl\u0131l\u0131k! T-LAB, ger\u00e7ekle\u015ftirmi\u015f oldu\u011fu ve hala devam eden cihaz ve protokol \u00e7al\u0131\u015fmalar\u0131 do\u011frultusunda milyarlarca vezik\u00fcl say\u0131s\u0131na ula\u015ft\u0131, mL\u2019de yakla\u015f\u0131k olarak 20 milyar vezik\u00fcl elde eden EXOMINE \u00fcr\u00fcn\u00fc alan\u0131nda zirveye yerle\u015fmi\u015f oldu. Son \u00fcr\u00fcn\u00fc yakla\u015f\u0131k olarak 5cc olan EXOMINE Kit, kullan\u0131c\u0131lar\u0131na 100 Milyar vezik\u00fcl sunuyor, bu say\u0131 alan\u0131nda ki rakip \u00fcr\u00fcnler aras\u0131nda en y\u00fcksek vezik\u00fcl say\u0131s\u0131 olarak g\u00f6sterilmekte. Y\u00fcksek vezik\u00fcl say\u0131s\u0131 her \u015fey demek de\u011fildir, elde edilen vezik\u00fcllere eksozom diyebilmek i\u00e7in boyutlar\u0131n\u0131n 80-120nm aras\u0131nda olmas\u0131, ilgili CD markerlar\u0131 ile analiz edilmesi ve canl\u0131l\u0131\u011f\u0131n y\u00fcksek olmas\u0131 gerekmektedir. EXOMINE \u00fcr\u00fcn\u00fc ile yap\u0131lan \u00e7al\u0131\u015fmalar do\u011frutusunda ortalama vezik\u00fcl boyutunun 116nm oldu\u011fu, ilgili CD markerlar\u0131 ile yap\u0131lan analizler sonucunda vezik\u00fcllerin %95\u2019inin tombosit kaynakl\u0131 eksozom oldu\u011fu ve canl\u0131l\u0131\u011f\u0131n ise %97 oran\u0131nda oldu\u011funu tarafs\u0131z laboratuvar sonu\u00e7lar\u0131 ile kan\u0131tlam\u0131\u015ft\u0131r. EXOMINE’nin Teknolojisi: Gen\u00e7lik H\u00fccrelerinde Sakl\u0131! EXOMINE Kit, PRP’nin i\u00e7erisindeki trombosit ve di\u011fer kan h\u00fccrelerini strese sokarak milyarlarca vezik\u00fcl salg\u0131lanmas\u0131n\u0131 sa\u011flar. \u00d6zel protokol ve cihazlar\u0131 ile trombositleri aktive ederek, trombosit kaynakl\u0131 eksozomlardan zengin otolog bir plazma sunar. Bu eksozomlar, mRNA, miRNA ve protein gibi biyolojik s\u00fcre\u00e7lerde \u00f6nemli rol oynayan bile\u015fenleri i\u00e7erir. EXOMINE Teknolojisiyle Tan\u0131\u015f\u0131n! Innovative PRX T\u00fcp Tasar\u0131m\u0131 ile Microlyzer B\u0131\u00e7ak Teknolojisi ayn\u0131 \u00fcr\u00fcnde bulu\u015ftu. T-LAB, kendine \u00f6zg\u00fc ve etkili bir yakla\u015f\u0131m olan EXOMINE teknolojisini geli\u015ftirdi. Bu inovasyon, Microlyzer Bi\u00e7ak Teknolojisi ve Geli\u015fmi\u015f PRX T\u00fcp ile bir araya getirilmi\u015ftir. Microlyzer B\u0131\u00e7ak Teknolojisi: Microlyzer 600\u03bcm \u00f6zel tasar\u0131m b\u0131\u00e7aklar\u0131 ve benzersiz yap\u0131s\u0131 ile kan h\u00fccrelerine etki ederek, milyarlarca vezik\u00fcl salg\u0131lanmas\u0131n\u0131 tetikler. Bu benzersiz teknoloji, kan h\u00fccrelerinin \u00f6zel bir stres alt\u0131nda sokarak, doku rejenerasyonu i\u00e7in gerekli olan eksozomlar\u0131n h\u00fccreler taraf\u0131ndan \u00fcretilmesini sa\u011flar. Geli\u015fmi\u015f PRX T\u00fcp: T-LAB’\u0131n uzman Ar-Ge ekibi, belirli boyut ve a\u011f\u0131rl\u0131ktaki kan h\u00fccrelerinin vezik\u00fcl sal\u0131n\u0131m\u0131n\u0131 art\u0131rmak ve trombosit h\u00fccrelerini mekanik olarak aktive etmek amac\u0131yla yo\u011fun \u00e7al\u0131\u015fmalar ger\u00e7ekle\u015ftirdi. Bu \u00e7abalar\u0131n \u00fcr\u00fcn\u00fc olarak, patentli \u00f6zel tasar\u0131m Geli\u015fmi\u015f PRX T\u00fcp ortaya \u00e7\u0131kt\u0131. T\u00fcp, \u00f6zel i\u00e7 tasar\u0131m\u0131 sayesinde h\u00fccrelerin milyarlarca vezik\u00fcl salg\u0131lamas\u0131n\u0131, trombosit h\u00fccrelerinin aktive olmas\u0131n\u0131 ve di\u011fer kan h\u00fccrelerinin dibe \u00e7\u00f6kmesini sa\u011flar. Bu da rejeneratif s\u00fcrecin etkinli\u011fini art\u0131rarak daha ba\u015far\u0131l\u0131 sonu\u00e7lar elde edilmesine olanak tan\u0131r. EXOMINE Teknolojisi, Microlyzer B\u0131\u00e7ak Teknolojisi ve Geli\u015fmi\u015f PRX T\u00fcp ile birle\u015ferek, trombosit kaynakl\u0131 eksozomlardan zengin otolog plazma uygulamalar\u0131nda yeni bir \u00e7\u0131\u011f\u0131r a\u00e7acak. T-LAB’\u0131n sa\u011fl\u0131k sekt\u00f6r\u00fcndeki liderli\u011fi, inovatif \u00e7\u00f6z\u00fcmleri ve s\u00fcrekli geli\u015fen teknolojisiyle \u00f6ne \u00e7\u0131kan EXOMINE \u00fcr\u00fcn\u00fc 2024 y\u0131l\u0131 itibariyle daha etkili ve verimli rejeneratif tedavilerin kap\u0131lar\u0131n\u0131 aralayacak. T-LAB’in Rejeneratif Miras\u0131 ve \u00c7\u0131\u011f\u0131r A\u00e7an EXOMINE Teknolojisi T-LAB, 2012 y\u0131l\u0131ndan bu yana rejeneratif t\u0131p alan\u0131nda \u00f6nc\u00fc bir rol oynayarak d\u00fcnya genelinde 2 milyonun \u00fczerinde PRP uygulamas\u0131na imza atm\u0131\u015ft\u0131r. T\u00fcrkiye’nin lider PRP kit \u00fcreticisi olan T-LAB, b\u00fcy\u00fck bir heyecan ve \u00f6zveri ile geli\u015ftirdi\u011fi EXOMINE teknolojisini 2023’\u00fcn son \u00e7eyre\u011finde hayata ge\u00e7irdi. Artan talep do\u011frultusunda s\u00fcrd\u00fcr\u00fclen Ar-Ge \u00e7al\u0131\u015fmalar\u0131 ve titiz test s\u00fcre\u00e7leri sonucunda EXOMINE, rejeneratif t\u0131p d\u00fcnyas\u0131nda bir d\u00f6n\u00fcm noktas\u0131 olacak bi\u00e7imde tasarland\u0131. Sene i\u00e7erisinde yap\u0131lan yo\u011fun Ar-Ge \u00e7al\u0131\u015fmalar\u0131 ve alan\u0131n\u0131n uzman hekimleri ile birlikte ger\u00e7ekle\u015ftirilen a\u015famalar, EXOMINE’in etkileyici \u00f6zelliklerini ortaya \u00e7\u0131kard\u0131. Microlyzer B\u0131\u00e7ak Teknolojisi ve Geli\u015fmi\u015f PRX T\u00fcp’\u00fcn birle\u015fimi, T-LAB\u2019in tart\u0131\u015f\u0131lmaz kalitesini ta\u015f\u0131yan yenilik\u00e7i bir teknolojiyi de ortaya \u00e7\u0131kard\u0131. Tamamlanan test a\u015famalar\u0131, EXOMINE’in \u00fcst d\u00fczey kalite ve performans standartlar\u0131n\u0131 kar\u015f\u0131lad\u0131\u011f\u0131n\u0131 g\u00f6sterdi. T-LAB, bu ba\u015far\u0131y\u0131 global bir \u00e7er\u00e7evede duyurarak, 2024’\u00fcn ilk \u00e7eyre\u011finde EXOMINE’i kullan\u0131ma sunma karar\u0131 ald\u0131. EXOMINE’in, geli\u015fmi\u015f PRP Kit, Non-Enzimatik SVF Kit ve di\u011fer T-LAB \u00fcr\u00fcnleriyle uyum i\u00e7inde \u00e7al\u0131\u015fmas\u0131, sa\u011fl\u0131k profesyonellerine geni\u015f bir yelpazede kullan\u0131m avantajlar\u0131 sunacak. EXOMINE ile T-LAB, PRP uygulamalar\u0131nda yeni bir d\u00f6nemi ba\u015flatarak 2023 sonunda imza att\u0131\u011f\u0131 yeni \u00fcr\u00fcn\u00fc ile estetik, ortobiyolojik ve terap\u00f6tik alanda \u00e7\u00f6z\u00fcmler sunmaya devam ediyor. T\u00fcrkiye’nin rejeneratif t\u0131p sekt\u00f6r\u00fcndeki lider markas\u0131 olan T-LAB, EXOMINE ile bir kez daha inovasyon ve kaliteyi bir araya getiriyor. Yenilik\u00e7i teknolojiler ve kaliteli \u00fcr\u00fcnleriyle T-LAB, sa\u011fl\u0131k profesyonellerine ve hastalara y\u00f6nelik \u00e7\u00f6z\u00fcmlerde 2024 liderli\u011fini s\u00fcrd\u00fcrmeye devam edecek. <\/p>","protected":false},"author":1,"featured_media":10889,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[69],"tags":[],"class_list":["post-10939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"views":1581,"_links":{"self":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts\/10939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/comments?post=10939"}],"version-history":[{"count":10,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts\/10939\/revisions"}],"predecessor-version":[{"id":12160,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts\/10939\/revisions\/12160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/media\/10889"}],"wp:attachment":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/media?parent=10939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/categories?post=10939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/tags?post=10939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}